A Phase 3, Open-Label Trial, Evaluating the Safety, Tolerability, and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Children Previously Partially Immunized With Prevenar.
Phase of Trial: Phase III
Latest Information Update: 22 Aug 2012
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
- Indications Pneumococcal infections
- Focus Adverse reactions; Pharmacodynamics
- 22 Sep 2010 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov.
- 22 Sep 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 21 Nov 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.